



Claims:


1. A pyrazole derivative represented by general formula (1A) or (1B), or pharmaceutically acceptable salt thereof:




5

wherein X represents β -D-glucopyranosyl group, wherein one or more hydroxyl groups may be acylated; Y represents a lower alkyl group or a perfluoro lower alkyl group; Z represents a cyclic alkyl group which may have a substituent(s), a cyclic unsaturated alkyl group which may have a substituent(s), a lower alkyl group having a cyclic alkyl group which may have a substituent(s), or a lower alkyl group having a cyclic unsaturated alkyl group which may have a substituent(s); R1 to R5 may be the same or different and each represent a hydrogen atom, a lower alkyl group, a perfluoro lower alkyl group, a lower alkoxy group, a perfluoro lower alkoxy group, a lower alkylthio group, a perfluoro lower alkylthio group, a lower alkylamino group, a halogeno group, a lower alkanoyl group, an alkenyl group, a cyclic alkenyl group, an alkynyl group, a phenyl group which may have a substituent(s), or a lower alkoxycarbonyl group; and n is an integer of 0 to 3.


2. The pyrazole derivative or pharmaceutically acceptable salt thereof according to claim 1, wherein, in formula (1A) or (1B), Y is trifluoromethyl group.
3. The pyrazole derivative or pharmaceutically acceptable salt thereof according to claim 1, wherein, in formula (1A) or (1B), Y is trifluoromethyl group and n is 1.
- 5 4. The pyrazole derivative or pharmaceutically acceptable salt thereof according to claim 1, wherein, in formula (1A) or (1B), Y is trifluoromethyl group, n is 1, and X is β -D-glucopyranosyl group, wherein one or more hydroxyl groups may be acylated with a group selected from the group consisting of an alkanoyl group having 2 to 20 carbon atoms, a lower alkoxycarbonyl group and a benzoyl group.
- 10 5. The compound or pharmaceutically acceptable salt thereof according to claim 1, selected from the group consisting of compounds shown below:




(2)



(3)



(4)




(5)

6. A pharmaceutical composition comprising the pyrazole derivative or
5 pharmaceutically acceptable salt thereof according to any one of claims 1 to 5.
7. A therapeutic agent for diabetes comprising the pyrazole derivative or
pharmaceutically acceptable salt thereof according to any one of claims 1 to 5.

8. An agent for inducing urinary sugar excretion comprising the pyrazole derivative or pharmaceutically acceptable salt thereof according to any one of claims 1 to 5.

9. Use of the pyrazole derivative or pharmaceutically acceptable salt thereof
 5 according to any one of claims 1 to 5 for reducing renal glucose reabsorption at renal uriniferous tubules.

10. A pyrazole-O-glycoside derivative represented by formula (I) or pharmaceutically acceptable salt thereof:



10

wherein X' represents β -D-glucopyranosyl group, wherein one or more hydroxyl groups may be acylated; Y' represents a hydrogen atom, a lower alkyl group, a fluoro lower alkyl group or a perfluoro lower alkyl group; Z' represents a halo
 15 lower alkyl group; and R₁' to R₅' may be the same or different and each represent a hydrogen atom, a halogeno group, a lower alkyl group, a halo lower alkyl group, a perfluoro lower alkyl group, a lower alkoxy group, a perfluoro lower alkoxy group, a lower alkylthio group, a perfluoro lower alkylthio group, a lower alkylamino group, a lower alkanoyl group, a lower alkenyl group, or a lower alkynyl group.

20 11. The pyrazole-O-glycoside derivative or pharmaceutically acceptable salt

thereof according to claim 10, wherein, in formula (I), X' is β -D-glucopyranosyl group, wherein one or more hydroxyl groups may be acylated with a group selected from the group consisting of an alkanoyl group having 2 to 20 carbon atoms, a lower alkoxycarbonyl group and a benzoyl group, Y' is trifluoromethyl group, and Z' is a halo lower alkyl group.



12. The pyrazole-O-glycoside derivative or pharmaceutically acceptable salt thereof according to claim 10, wherein, in formula (I), X' is β -D-glucopyranosyl group wherein one or more hydroxyl groups may be acylated with a group selected from the group consisting of an alkanoyl group having 2 to 20 carbon atoms, a lower alkoxycarbonyl group and a benzoyl group, Y' is trifluoromethyl group, and Z' is a fluoro lower alkyl group.

13. The pyrazole-O-glycoside derivative or pharmaceutically acceptable salt thereof according to claim 10, wherein, in formula (I), X' is β -D-glucopyranosyl group, wherein one or more hydroxyl groups may be acylated with a group selected from the group consisting of an alkanoyl group having 2 to 20 carbon atoms, a lower alkoxycarbonyl group and a benzoyl group, Y' is methyl group, and Z' is a halo lower alkyl group.

14. The pyrazole derivative or pharmaceutically acceptable salt thereof according to claim 10, wherein, in formula (I), X' is β -D-glucopyranosyl group, wherein one or more hydroxyl groups may be acylated with a group selected from the group consisting of an alkanoyl group having 2 to 20 carbon atoms, a lower alkoxycarbonyl group and a benzoyl group, Y' is methyl group, and Z' is a fluoro lower alkyl group.

15. The compound or pharmaceutically acceptable salt thereof according to claim

10, selected from the group consisting of compounds shown below:



16. A pharmaceutical composition comprising the pyrazole-O-glycoside derivative or pharmaceutically acceptable salt thereof according to any one of claims 10 to 15.

17. A therapeutic agent for diabetes comprising the pyrazole-O-glycoside derivative or pharmaceutically acceptable salt thereof according to any one of claims 10 to 15.

18. A therapeutic agent for diabetes for oral administration, comprising the pyrazole-O-glycoside derivative or pharmaceutically acceptable salt thereof according to any one of claims 10 to 15.

19. An agent for inducing urinary sugar excretion comprising the pyrazole-O-glycoside derivative or pharmaceutically acceptable salt thereof according to any one of claims 10 to 15.

20. Use of the pyrazole-O-glycoside derivative or pharmaceutically acceptable salt

thereof according to any one of claims 10 to 15 for reducing renal glucose reabsorption at renal uriniferous tubules.